Objective: To study the variation in genistein þ daidzein intake over a 6-month period and test the reliability of 24 h urinary isoflavones as a biomarker of exposure over time. Design: Dietary genistein þ daidzein intake was assessed at various time points throughout six months in 15 healthy subjects. Group 1 (n ¼ 8) followed nonsupplemented diets and Group 2 (n ¼ 7) took a 35 mg/d isoflavone supplement for 3 months and each subject provided a 24 h urine collection, validated with para-aminobenzoic acid, during weeks 7, 15 and 19. Urine was analysed for genistein and daidzein using LC-MS. Results: Isoflavone intake in Groups 1 and 2 ranged from 0.00 to 1.1 mg/d and 0.1 to 53.1 mg/d, respectively. Urine excretion for both groups ranged from 0.20 to 9.56 mg/d. The relationship between 24 h excretion and isoflavone intake is y ¼ 0.44 Â 70.03(standard deviation) þ 1.57; r ¼ 0.89, Po0.001.
Introduction
Phyto-oestrogens are compounds capable of mimicking the biological effects of oestrogens (Mazur & Adlercreutz, 1998) . Two principal isoflavones in the diet are genistein and daidzein, mainly found in soy. Populations consuming soy (such as the Japanese) have much lower rates of breast and prostate cancer (Griffiths et al, 1996) and hence the potential anti-oxidant and anti-cancer properties of the soy isoflavones have been the basis for extensive research in this area of phytochemistry and nutrition.
Although previous studies (Arai et al, 2000; Nagata, 2000; Verkasalo et al, 2001 ) have indicated a relationship between isoflavone intake and urinary excretion or concentrations of isoflavones in plasma, there appears to have been no investigation of this relationship over a large range of dietary isoflavone intakes (0-50 mg/d) over a considerable period of time that is, several weeks to several months.
This time-course study was designed to investigate the variation in total genistein þ daidzein intake and 24 h urinary excretion (ie test the reliability of the biomarker) over 6 months, during which time subjects should be exposed to a range of isoflavone intakes.
Methods
A total of 66 healthy pre-menopausal women suffering from breast pain were initially recruited and 15 healthy pre-menopausal women, aged 30-51 y, with a regular menstrual cycle completed the study. Prior to starting the study, all subjects underwent a breast check.
Ethical approval was granted prior to study commencement and all subjects gave written consent.
Study Protocol (Figure 1) At the start of the study, subjects took a placebo tablet for 1 month. Only subjects who did not respond to placebo (breast pain reduction less than 30%) continued in the study (as per protocol). All 24 h urine collections were validated using para-aminobenzoic acid (PABA) (Bingham & Cummings, 1983) . During the 3-month supplementation phase, 50% of the subjects were given a placebo tablet (Group 1) and 50% were given an active tablet containing 35 mg isoflavones/d (Group 2).
Compliance during food recording was checked by use of energy intake (EI) and basal metabolic rate (BMR), calculated using the Schofield equations (Schofield et al, 1985) . For food records to reflect dietary intake accurately the EI:BMR ratio should be greater than 1.2. Subject weight (kg) at the start of the study was recorded and used in the calculation of body mass index (BMI) ( Table 1) .
Isoflavones used for this study were extracted from red clover and supplied by Novogen PLC. The formulation of the tablet was in the ratio, 2.0-4.0 : 1 (Biochanin A þ Genistein : Daidzein þ Formononetin). The ratio was a constant and all tablets were from the same batch.
All estimated food diaries (7 d and 3 Â 2 d) were analysed for total genistein and daidzein content using Microdiets and the newly constructed phyto-oestrogen database (Ritchie 2003, Ritchie et al, 2004) .
Toxicity
A plasma sample was provided by each volunteer prior to and at the end of the 3-month intervention phase of the study. Each plasma sample was analysed for gamma glutamyl transferase, alkaline phosphatase, alanine amino transferase, aspartate amino transferase, urea, protein (albumin), electrolytes and creatinine. Figure 1 Protocol for the study. Time-course study investigating the long-term variation in PE intake monitored by the use of a biomarker.
Analytical methods
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Sample hydrolysis and extraction
Urine samples were prepared according to the method of Pumford et al (2002) and Morton et al (2002) , but omitting the derivatisation step. Samples were further cleaned up (delipidized) by LH -20 chromatography. Finally, samples were dissolved in 80 ml of 50% methanol/water and stored at À201C prior to LC-MS analysis.
LC-MS analysis LC-MS was carried out by monitoring of the analyte and internal standard molecular ions, MH þ . A ThermoFinnigan Liquid Chromatography Quadrupole (LCQ-Deca) ion trap mass spectrometer with an on-axis electrospray interface fitted with a Surveyor Autosampler was used.
Statistical analysis
All statistical analysis was performed using Microsoft Excel 97. Data are given as mean (7 standard error).
Results
Subject characteristics and compliance
For all subjects taking the supplement, urinary isoflavone excretion increased and remained high during the period of supplementation as has been demonstrated in a previous intervention study (Ritchie et al, 2004b) (Table 1) , therefore compliance was excellent as demonstrated in Figure 2 . For all subjects the mean ratio of EI:BMR ranged from 1.2 to 1.6, indicating adequate dietary intake and food recording during each specified period throughout the study (Table 1) . The mean age, PABA recovery, BMI, EI:BMR, dietary isoflavone intake and excretion for each group are reported in Table 1 . The relationship between 24 h excretion and isoflavone intake is y ¼ 0.44x70.03(standard deviation) þ 1.57; r ¼ 0.89, Po0.001 (n ¼ 45) (Figure 2 ). When intake and urine values were averaged for the periods of nonsupplementation and the two periods of supplementation, the relationship between 24 h excretion and isoflavone intake is y ¼ 0.46x70.03(standard deviation) þ 1.50; r ¼ 0.93, Po0.001 (n ¼ 22), data and figure not shown.
There was no evidence of toxicity. The difference in mean baseline isoflavone intake and intake during the nonsupplementation phase between the groups was not significant. In addition, the difference in urine excretion between both recording periods and both groups was not significant. During supplementation, there was no significant difference in the mean isoflavone intake and urine excretion between the two recording/collection days.
Conclusion
The results of this study indicate that 24 h urine collections can be used as a marker of compliance during isoflavone intervention studies lasting several months and a 24 h urine collection can be used as a biomarker of phyto-oestrogen intake over a range of intakes from 0 to 51 mg/d.
The use of such a biomarker will assist future epidemiological studies by more accurately assessing dietary phyto-oestrogen exposure. This may benefit further disease related research, where the relationship between dietary phyto-oestrogen intake and relative risk of research can be investigated. In addition, subject compliance can be measured during long-term phyto-oestrogen studies by the use of this biomarker.
